Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
40.53
+0.63 (1.58%)
Dec 22, 2025, 2:32 PM EST - Market open
Terns Pharmaceuticals Employees
Terns Pharmaceuticals had 59 employees as of December 31, 2024. The number of employees decreased by 7 or -10.61% compared to the previous year.
Employees
59
Change (1Y)
-7
Growth (1Y)
-10.61%
Revenue / Employee
n/a
Profits / Employee
-$1,600,593
Market Cap
4.31B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59 | -7 | -10.61% |
| Dec 31, 2023 | 66 | 20 | 43.48% |
| Dec 31, 2022 | 46 | 5 | 12.20% |
| Dec 31, 2021 | 41 | 11 | 36.67% |
| Dec 31, 2020 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TERN News
- 10 days ago - Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 12 days ago - Terns Announces Pricing of Upsized $650 Million Public Offering - GlobeNewsWire
- 12 days ago - Cancer Study Buoys These Small Biotechs - Barrons
- 12 days ago - Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again - Seeking Alpha
- 13 days ago - Terns Announces Proposed Public Offering - GlobeNewsWire
- 13 days ago - Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript - Seeking Alpha
- 13 days ago - Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting - GlobeNewsWire
- 5 weeks ago - Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London - GlobeNewsWire